Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 4

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06641765Not ApplicableActive Not Recruiting

Continuous Glucose Monitoring in Dialysis Patients With Diabetes

Role: lead

NCT06675903Recruiting

Continuous Glucose Monitoring (CGM) After Kidney Transplantation

Role: lead

NCT04579315Not ApplicableCompleted

Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease

Role: lead

NCT02237521Completed

The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease

Role: lead

NCT02284230Phase 2Withdrawn

The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

Role: lead

NCT01800188Completed

Glucose Metabolism During Hemodialysis

Role: lead

NCT01394341Phase 4Completed

Liraglutide Treatment to Patients With Severe Renal Insufficiency

Role: lead

NCT01391884Completed

Elimination of Incretin Hormones in Patients With Severe Kidney Failure

Role: lead

All 8 trials loaded